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Abstract
The laterocapsular division of the central nucleus of the amygdala (CeLC) has emerged as an
important site of pain-related plasticity and pain modulation. Glutamate and neuropeptide
receptors in the CeLC contribute to synaptic and behavioral changes in the arthritis pain model,
but the intracellular signaling pathways remain to be determined. This study addressed the role of
PKA, PKC, and ERK in the CeLC. Adult male Sprague-Dawley rats were used in all experiments.
Whole-cell patch-clamp recordings of CeLC neurons were made in brain slices from normal rats
and from rats with a kaolin/carrageenan-induced monoarthritis in the knee (6 h postinduction).
Membrane-permeable inhibitors of PKA (KT5720, 1 μM; cAMPS-Rp, 10 μM) and ERK (U0126, 1
μM) activation inhibited synaptic plasticity in slices from arthritic rats but had no effect on normal
transmission in control slices. A PKC inhibitor (GF109203x, 1 μM) and an inactive structural
analogue of U0126 (U0124, 1 μM) had no effect. The NMDA receptor-mediated synaptic
component was inhibited by KT5720 or U0126; their combined application had additive effects.
U0126 did not inhibit synaptic facilitation by forskolin-induced PKA-activation. Administration of
KT5720 (100 μM, concentration in microdialysis probe) or U0126 (100 μM) into the CeLC, but
not striatum (placement control), inhibited audible and ultrasonic vocalizations and spinal reflexes
of arthritic rats but had no effect in normal animals. GF109203x (100 μM) and U0124 (100 μM) did
not affect pain behavior. The data suggest that in the amygdala PKA and ERK, but not PKC,
contribute to pain-related synaptic facilitation and behavior by increasing NMDA receptor function
through independent signaling pathways.
Introduction
The present study focused on the role of intracellular sig-
naling mechanisms in the amygdala in pain-related plas-
ticity and behavior. The amygdala is now recognized as an
important player in the emotional-affective dimension of
pain [1-9]. The laterocapsular division of the central
nucleus of the amygdala (CeLC) is of particular impor-
tance, because it receives nociceptive ("pain-related")
information directly from spinal cord and brainstem and
indirectly, through the lateral-basolateral amygdala cir-
cuitry, from thalamus and cortex [1,8]. Our previous stud-
ies demonstrated central sensitization [10-15] and
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synaptic plasticity [10,16-19] in the CeLC in the kaolin/
carrageenan-induced arthritis pain model. Recent imaging
data also showed increased amygdala activation related to
knee pain in patients with osteoarthritis [20]. Pain-related
synaptic plasticity in the CeLC was confirmed in a model
of chronic neuropathic pain [3] and was mimicked by
tetanic stimulation of presumed nociceptive inputs from
the brainstem [21].
A consequence of pain-related amygdala activation is
increased pain behavior. Deactivation of the central
nucleus decreased nocifensive and affective behavior asso-
ciated with arthritic [9,10,22], formalin-induced [[2]; but
see Tanimoto et al., 2003], visceral [23-25], and neuro-
pathic pain [4]. However, the amygdala is also important
for pain inhibition, particularly in the context of stress-
induced and conditioned forms of analgesia [26-32]. The
conditions under which the amygdala assumes pro- or
anti-nociceptive functions and the underlying mecha-
nisms remain to be determined.
Arthritis pain-related synaptic plasticity and central sensi-
tization in the CeLC require the upregulation of presynap-
tic metabotropic glutamate receptors [12,16] and
increased postsynaptic NMDA receptor function through
a mechanism that involves NR1 phosphorylation by PKA
[13,17]. Pain-related PKA activation in the CeLC appears
to occur downstream of calcitonin gene-related peptide
receptor CGRP1 [10] and corticotropin-releasing factor
receptor CRF1[11,33]. Protein kinases such as PKA, PKC,
and ERK, play important roles in the central sensitization
of spinal cord neurons [34-40]. The effects of PKA and
PKC activators on spinal transmission and excitability
were blocked by inhibitors of ERK signaling, suggesting
that PKA and PKC are upstream activators of ERK in the
spinal cord [39,40].
Pain-related functions and interactions of protein kinases,
including PKA, PKC, and ERK, in the amygdala are largely
unknown. A recent biochemical and behavioral study
showed ERK activation in the CeLC in the formalin pain
model and antinociceptive effects of inhibiting ERK acti-
vation in the CeLC [2]. The present study used a multidis-
ciplinary approach at the cellular and system levels to
determine the effects of selective inhibitors of PKA, PKC,
and ERK in the amygdala on pain-related synaptic plastic-
ity and behavior. We focused on these protein kinases
because they are important for spinal central sensitization
and can phosphorylate the NMDA receptor [41-43],
which is a critical mechanism of arthritis pain-related
plasticity in the amygdala [17].
Methods
All experimental procedures were approved by the Institu-
tional Animal Use and Care Committee (IACUC) at the
University of Texas Medical Branch and conform to guide-
lines of the International Association for the Study of Pain
(IASP) and of the National Institutes of Health (NIH).
Electrophysiological and behavioral data were obtained
from normal rats (n = 34) and from rats with an acute
monoarthritis (n = 60; see below). Adult male Sprague-
Dawley rats (120–250 g) were used for all experiments, 94
animals in total. Rats were individually housed in stand-
ard plastic boxes (40 × 20 cm) in a temperature-controlled
room and maintained on a 12 h day and night cycle.
Standard laboratory chow and tap water was continuously
available. On the day of the experiment, rats were trans-
ferred from the animal facility and allowed to acclimate to
the laboratory for at least 1 h.
Arthritis pain model
In some animals (n = 60) a localized mono-arthritis was
induced in the left knee. For arthritis induction, animals
were briefly (for 20 min) anesthetized either with the
short-acting barbiturate sodium methohexital (Brevital®,
50 mg/kg, i.p.) or with 5% isoflurane (1-chloro-2,2,2-trif-
luoroethyl difluoromethyl ether; Hospira Inc. Lake Forest,
IL, USA) using an Ohio Isoflurane Vaporizer (100F
model). Since no differences in electrophysiological and
behavioral changes were found, data were pooled. A kao-
lin suspension (4%, 80–100 μl) was injected into the joint
cavity through the patellar ligament with a syringe (1 ml,
25 G5/8). After repetitive flexions and extensions of the
knee for 15 min, a carrageenan solution (2%, 80–100 μl)
was injected into the knee joint cavity and the leg was
flexed and extended for another 5 min. This treatment
paradigm reliably leads to inflammation and swelling of
the knee within 1–3 h, reaches a maximum plateau at 5–
6 h, and persists for days [44]. The monoarthritis is strictly
confined to the knee; it does not spread and become sys-
temic; and it is a use-dependent pain model, i.e., signs of
"spontaneous" pain are typically not observed in the
absence of external stimulation or movement [44]. Ani-
mals recovered quickly and were closely monitored for
any signs of distress, using a "Quantitative Assessment for
Pain and Distress Chart" provided by our IACUC. Param-
eters included overall appearance, breathing patterns,
grooming behavior, locomotion around the cage, water
and food consumption, spontaneous vocalizations, and
interactions with the investigator. Electrophysiological
and behavioral measurements of arthritis pain-related
changes were made 6 h after arthritis induction (plateau
phase, see above). During the development of arthritis the
animals were without the benefit of anesthesia or analge-
sics. The addition of any analgesics or continuous
anesthesia would preclude the measurement of pain-
related behavior and affect neuronal activity in the brain
slice by chemical contamination to such extent that it
would invalidate the data and confound the results and
interpretation.Molecular Pain 2008, 4:26 http://www.molecularpain.com/content/4/1/26
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Electrophysiology: patch clamp recording
Amygdala slice preparation
Brain slices containing the central nucleus of the amy-
gdala (CeA) were obtained from 51 rats. Rats were decap-
itated without the use of anesthesia to avoid chemical
contamination of the tissue. The brain was quickly dis-
sected out and blocked in cold (4°C) artificial cerebrospi-
nal fluid (ACSF). ACSF contained (in mM): NaCl 117, KCl
4.7, NaH2PO4 1.2, CaCl2 2.5, MgCl2 1.2, NaHCO3 25, and
glucose 11. ACSF was oxygenated and equilibrated to pH
7.4 with a mixture of 95% O2/5% CO2. Coronal brain
slices (500 μm) were prepared using a Vibroslice (Cam-
den Instruments, London, UK). After incubation in ACSF
at room temperature (21°C) for at least 1 h, a single brain
slice was transferred to the recording chamber and sub-
merged in ACSF (31 ± 1°C), which perfused the slice at a
rate of ~2 ml/min. Only 1–2 brain slices per animal were
used, and only 1 neuron was recorded in each slice.
Unless otherwise stated, numbers in the manuscript refer
to the number of neurons tested for each parameter.
Whole-cell patch-clamp recording
Recordings were made in the right amygdala because our
previous electrophysiological in vivo and in vitro studies
showed pain-related plasticity in the right amygdala
[10,11,15-17,45] and our behavioral data indicated that
the right amygdala is coupled to pain facilitation in the
arthritis pain model [10,22,45]. This is consistent with a
strong contralateral projection of the spino-parabrachio-
amygdaloid pain pathway [1,46] (arthritis was induced in
the left knee).
Whole-cell recordings using the "blind" patch technique
were obtained from neurons in the latero-capsular divi-
sion of the CeA (CeLC) as described before [10,16-19].
The different nuclei of the amygdala and the CeA subdivi-
sions are easily discerned under the microscope. Patch
electrodes (4–6 MΩ tip resistance) were made from boro-
silicate glass capillaries (1.5 mm and 1.12 mm, outer and
inner diameter, respectively; Drummond, Broomall, PA),
using a Flaming-Brown micropipette puller (P-80/PC,
Sutter Instrument Co., Novato, CA). The internal solution
of the recording electrodes contained (in mM): 122 K-glu-
conate, 5 NaCl, 0.3 CaCl2, 2 MgCl2, 1 EGTA, 10 HEPES, 5
Na2-ATP, 0.4 Na3-GTP; pH was adjusted to 7.2–7.3 with
KOH and the osmolarity to 280 mOsm/kg with sucrose.
After tight (>2 GΩ) seals were formed and the whole-cell
configuration was obtained, neurons were included in the
sample if the resting membrane potential was more nega-
tive than -50 mV and action potentials overshooting 0 mV
were evoked by direct depolarizing current injections.
Voltage and current signals were low-pass filtered at 1 kHz
with a dual 4-pole Bessel filter (Warner Instrument Corp.,
Hamden, CT), digitized at 5 kHz (Digidata 1322A inter-
face, Axon Instr., Molecular Devices, Sunnyvale, CA), and
stored on a computer (Dell Pentium 4). Data were also
continuously recorded on an ink chart recorder (Gould
3400, Gould Instr., Valley View, OH). Current- and volt-
age-clamp (d-SEVC) recordings were made using an
Axoclamp-2B amplifier (Axon Instr.) with a switching fre-
quency of 5–6 kHz (30% duty cycle), gain of 3–8 nA/mV,
and time constant of 20 ms. Phase shift and anti-alias fil-
ter were optimized. The headstage voltage was monitored
continuously on a digital oscilloscope (Gould 400, Gould
Instr.) to ensure precise performance of the amplifier. If
series resistance (monitored with pCLAMP9 software,
Axon Instr.) changed more than 10%, the neuron was dis-
carded. Voltage- and current data were analyzed with
pCLAMP9 software (Axon Instruments). Neurons were
voltage-clamped at -60 mV except for the analysis of
NMDA receptor-mediated synaptic transmission
(recorded at +20 mV).
Synaptic stimulation
Using two concentric bipolar stimulating electrodes (SNE-
100, Kopf Instr.; 22 kΩ), monosynaptic excitatory postsy-
naptic currents (EPSCs) were evoked in CeLC neurons by
electrical stimulation (using a Grass S88 stimulator) of
two distinct lines of input [1,3,8,21]: the PB-CeLC syn-
apse, which contains afferents from the lateral parabra-
chial area and provides presumed nociceptive input from
the spino-parabrachio-amygdaloid pain pathway, and the
BLA-CeLC synapse, which transmits highly integrated pol-
ymodal information from thalamic and cortical areas and
is part of the fear/anxiety circuitry. For stimulation of the
PB-CeLC synapse, the electrode was positioned under
microscopic control on the afferent fiber tract from the lat-
eral PB, which runs dorsomedial to the CeA and ventral to
but outside of the caudate-putamen. In the vicinity of this
tract, no other afferents to the CeA have been described
[47-49]. Electrical stimuli (150 μs square-wave pulses)
were delivered at low frequencies (<0.25 Hz). Input-out-
put functions were obtained by increasing the stimulus
intensity in 100 μA steps (see Figure 1). For evaluation of
a drug effect on synaptically evoked responses, the stimu-
lus intensity was adjusted to 75–80% of the intensity
required for orthodromic spike generation [10,16,17].
Drugs
The following membrane-permeable selective protein
kinase inhibitors were used: (9R,10S,12S)-2,3,9,10,11,12-
hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo [1,2,3-fg:3',2',1'-kl]pyrrolo [3,4-i][1,6]benzodia-
zocine-10-carboxylic acid, hexyl ester (KT5720, a potent
and selective PKA inhibitor[17,50]); (R)-adenosine, cyclic
3',5'-(hydrogenphosphorothioate) triethylammonium
(cAMPS-Rp, a competitive cAMP antagonist[51]); 1,4-
diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)buta-
diene (U0126, a selective ERK inhibitor[52]); 1,4-Molecular Pain 2008, 4:26 http://www.molecularpain.com/content/4/1/26
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diamino-2,3-dicyano-1,4-bis(methylthio)butadiene
(U0124, inactive analogue of U0126 [52]); and 2-[1-(3-
dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) male-
imide (GF109203x, a potent and selective PKC inhibi-
tor[53]). For the analysis of NMDA receptor-mediated
transmission we used DL-2-amino-5-phosphonopenta-
noic acid (AP5, NMDA receptor antagonist), 2,3-dioxo-6-
nitro-1,2,3,4-tetrahydrobenzo [f]quinoxaline-7-sulfona-
mide disodium salt (NBQX, non-NMDA receptor antago-
nist), and [R-(R*,S*)]-6-(5,6,7,8-tetrahydro-6-methyl-
1,3-dioxolo [4,5-g]isoquinolin-5-yl)furo [3,4-e]-1,3-ben-
zodioxol-8(6H)-one (bicuculline, GABAA receptor antag-
onist). All drugs were purchased from Tocris Bioscience,
Ellisville, MO, USA. Drugs were dissolved in ACSF on the
day of the experiment and applied to the brain slice by
gravity-driven superfusion in the ACSF (~2 ml/min).
Synaptic plasticity in CeLC neurons in the arthritis pain model Figure 1
Synaptic plasticity in CeLC neurons in the arthritis pain model. Input-output functions of CeLC neurons were meas-
ured in slices from arthritic animals (6 h postinduction) and in slices from normal animals. Monosynaptic excitatory postsynap-
tic currents (EPSCs) were evoked in CeLC neurons by electrical stimulation of the PB-CeLC (A) and BLA-CeLC (B) synapses 
with increasing intensities. Input-output curves were generated by plotting peak EPSC amplitude (pA) as a function of afferent 
fiber volley stimulus intensity (μA). Input-output functions of neurons from arthritic animals (n = 19) were significantly different 
from those of control neurons (n = 16) at the PB-CeLC (P < 0.0001, F 1,363 = 66.65) and BLA-CeLC (P < 0.0001, F 1,363 = 43.30, 
two-way ANOVA) synapses. Individual traces (mean of 8–10 trials) show monosynaptic EPSCs recorded in one CeLC neuron 
from a normal rat and another CeLC neuron from an arthritic rat. Whole-cell voltage-clamp recordings were made at -60 mV. 
* P < 0.05, ** P < 0.01, *** P < 0.001 (Bonferroni post-tests).
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Solution flow into the recording chamber (1 ml volume)
was controlled with a three-way stopcock. Drugs were
applied for at least 15 min to establish equilibrium in the
tissue. Based on our previous studies and initial observa-
tions showing that drug effects reached a plateau after 10
min, the 12–15 min time point was selected for the anal-
ysis of drug effects on synaptic transmission. In some
experiments KT5720 was included in the internal pipette
solution for direct application into the cell.
Behavior: vocalizations and hindlimb withdrawal reflexes
For behavioral tests 43 rats were used.
Experimental protocol
A guide cannula for ACSF and drug application by micro-
dialysis was stereotaxically implanted i n  t h e  C e L C  ( o r
striatum as placement control). The next day, vocaliza-
tions and spinal withdrawal reflexes were measured in 2
groups of animals. Rats in the "normal" group were tested
before (ACSF vehicle control) and during drug adminis-
tration (15 min). The "arthritis" group was tested before
arthritis induction (baseline), 6 h postinduction of arthri-
tis (ACSF vehicle predrug control), during drug adminis-
tration (15 min), and after drug administration (30 min
washout with ACSF). ACSF served as a vehicle control
because drugs were dissolved in ACSF. Arthritis was
induced as described under "Arthritis pain model". At the
end of the experiment, the animal was sacrificed by decap-
itation under anesthesia with pentobarbital (Nembutal,
50 mg/kg, i.p.).
Microdialysis for drug application
Drugs were administered into the right CeLC contralateral
to the arthritis (see 2.2.2). As described in detail before
[9,10,22], rats were anaesthetized with pentobarbital
sodium (50 mg/kg, i.p.) and a small unilateral craniot-
omy was performed at the sutura fronto-parietalis level.
Using a stereotaxic apparatus (David Kopf Instr., Tujunga,
CA), a guide cannula was implanted on the dorsal margin
of the CeLC using the following coordinates [54]: 2.0 ±
0.1 mm caudal to bregma, 4.0 mm lateral to midline,
depth 7.0 mm. In some experiments a guide cannula was
implanted into the striatum as a placement control, using
the following stereotaxic coordinates 2.0 ± 0.1 mm caudal
to bregma; 4.5 mm lateral to midline; depth of tip 5.0
mm. The cannula was fixed to the skull with dental acrylic
(PlasticsOne, Roanoke, VA). Antibiotic ointment was
applied to the exposed tissue to prevent infection. On the
day of the experiment a microdialysis probe (CMA/Micro-
dialysis 11; membrane diameter: 250 μm, membrane
length: 1 mm) was inserted into the CeLC through the
guide cannula so that the probe protruded by 1 mm.
Using PE-50 tubing, the probe was connected to a Harvard
infusion pump and perfused with ACSF (2 μl/min) con-
taining (in mM): NaCl 125.0, KCl 2.6, NaH2PO4 2.5,
CaCl2 1.3, MgCl2 0.9, NaHCO3 21.0, and glucose 3.5; oxy-
genated and equilibrated to pH = 7.4. Before each drug
application, ACSF was pumped through the fiber for at
least 1 h to establish equilibrium in the tissue.
Drugs
Protein kinase inhibitors (same as in Electrophysiology)
were dissolved in ACSF on the day of the experiment at a
concentration 100 times that predicted to be needed
based on published biochemical data [50,51,53], our pre-
vious microdialysis study[33], and our in vitro data [[10];
and this study, [17]] because of the concentration gradient
across the dialysis membrane and diffusion in the tissue
[10-14]. The numbers given in this article refer to the drug
concentrations in the microdialysis fiber. ACSF adminis-
tered alone served as a vehicle control. Behavior was
measured at 15 min during continued drug administra-
tion and again at 30 min of washout with ACSF.
Audible and ultrasonic vocalizations
Vocalizations were recorded and analyzed as described in
detail previously [22]. The experimental setup (US Patent
7,213,538) included a custom designed recording cham-
ber, a condenser microphone (audible range: 20 Hz-16
kHz) connected to a preamplifier, an ultrasound detector
(25 ± 4 kHz), filter and amplifier (UltraVox 4-channel sys-
tem, Noldus Information Technology, Leesburg, VA).
Data acquisition software (UltraVox 2.0; Noldus Informa-
tion Technology) automatically monitored the occurrence
of vocalizations within user-defined frequencies and
recorded the number and duration of digitized events
(audible and ultrasonic vocalizations). Audible and ultra-
sonic vocalizations were recorded simultaneously with
the two microphones connected to separate channels of
the amplifier. The computerized recording system was set
to suppress non-relevant audible sounds (background
noise) and to ignore ultrasounds outside the defined fre-
quency range.
Animals were placed in the recording chamber for accli-
mation 1 h before the vocalization measurements. The
recording chamber ensured the stable positioning of the
animal at a fixed distance from the sound detectors and
allowed the reproducible stimulation of the knee joint
through openings for the hind limbs. Brief (15 s) innocu-
ous (100 g/30 mm2) and noxious (2000 g/30 mm2)
mechanical stimuli were applied to the knee, using a cali-
brated forceps equipped with a force transducer, the out-
put of which was displayed on an LCD screen [10,55]. The
chamber also had an opening for drug administration
through the microdialysis probe inserted into the
implanted guide cannula. The total duration of vocaliza-
tions (arithmetic sum of the duration of individual
events) was recorded for 1 min, starting with the onset of
the mechanical stimulus. Audible and ultrasonic vocaliza-Molecular Pain 2008, 4:26 http://www.molecularpain.com/content/4/1/26
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tions reflect supraspinally organized nocifensive and
affective responses to aversive stimuli [44,56].
Hindlimb withdrawal reflex
Thresholds of spinal withdrawal reflexes evoked by
mechanical stimulation of the knee joint were measured
subsequently to the vocalization measurements as
described in detail before [44,55]. Mechanical stimuli of
continuously increasing intensity were applied to the knee
joint, using a calibrated forceps with a force transducer as
in the vocalization experiments. Withdrawal threshold
was defined as the minimum stimulus intensity that
evoked a withdrawal reflex.
Histology
At the end of each behavioral experiment, the position of
the microdialysis probe in the CeLC or striatum (place-
ment control) was confirmed histologically. The brain
was removed and submerged in 10% formalin. Tissues
were stored in 20% sucrose before they were frozen sec-
tioned at 50 μm. Sections were stained with Neutral Red,
mounted on gel-coated slides and cover-slipped. Lesion
sites were plotted on standard diagrams.
Data analysis and statistics
All averaged values are given as the mean ± SEM. Statisti-
cal significance was accepted at the level P < 0.05. Graph-
Pad Prism 3.0 software (GraphPad Software Inc., San
Diego, CA) was used for all statistical analyses.
Electrophysiology
Input-output functions were compared using repeated-
measures two-way analysis of variance (ANOVA) fol-
lowed by Bonferroni post-tests. The paired t-test was used
to compare evoked EPSC amplitudes before and after a
single drug application in the same neuron. Time-course
data of the effects of a single drug were compared to pre-
drug values in the same neuron using repeated-measures
ANOVA followed by Dunnett's Multiple Comparison
Test. Repeated-measures ANOVA followed by Bonferroni
post-tests was used to compare the effects of more than
one drug in the same neuron to predrug control values
and to each other.
Behavior
The duration of audible and ultrasonic vocalizations was
calculated as the arithmetic sum (total amount) of the
durations of individual vocalization events in a 1 min
recording period. Vocalizations and withdrawal thresh-
olds of the same animal before and after arthritis and
before and during drug application in arthritis were com-
pared using repeated-measures ANOVA followed by Bon-
ferroni post-tests ("arthritis" group, see Experimental
protocol). The paired t-test was used to compare behavior
before and during drug administration in normal animals
("normal" group).
Results
Enhanced synaptic transmission in CeLC neurons in the 
arthritis pain model
Whole-cell patch-clamp recordings were made of neurons
in the latero-capsular division of the central nucleus of the
amygdala (CeLC) in brain slices from normal rats (n = 26
neurons) and from arthritic rats (6 h postinduction; n =
35 neurons) in 51 animals. Recordings were made in the
right amygdala because of the strong contralateral projec-
tion of the spino-parabrachio-amygdaloid pain pathway
[1,46] (arthritis was induced in the left knee). The right
amygdala develops pain-related plasticity [10,11,15-
17,45] and is coupled to pain facilitation [10,22,45] in the
arthritis pain model.
Only 1 or 2 brain slices per animal were used and 1 neu-
ron was recorded in each slice. Like most CeLC neurons
[1,3,21], all CeLC neurons in this study responded to elec-
trical stimulation of the PB-CeLC synapse and the BLA-
CeLC synapse (see "Synaptic stimulation" in Methods).
Based on their action potential firing properties these neu-
rons were non-accommodating repetitive- and regular-
spiking, which is the prevalent type of neurons in this
division of the amygdala [16,57-59].
In agreement with our previous studies [10,16,17,19]
enhanced synaptic transmission was recorded in the CeLC
in brain slices from arthritic rats compared to control
CeLC neurons from normal rats (Figure 1). Analysis of
input-output functions showed increased synaptic
strength measured as increased peak amplitudes of mon-
osynaptic excitatory postsynaptic currents (EPSCs) evoked
at the PB-CeLC synapse (Figure 1A; P < 0.0001, F 1,363 =
66.65) and the BLA-CeLC synapse (Figure 1B; P < 0.0001,
F  1,363 = 43.30, two-way ANOVA) in the arthritis pain
model (n = 19 neurons) compared to normal transmis-
sion (n = 16 neurons). Enhanced synaptic transmission
preserved in the slice preparation indicates "synaptic plas-
ticity" because it is maintained independently of periph-
eral or spinal mechanisms [1].
Inhibition of PKA activation decreases pain-related 
synaptic plasticity
A selective membrane-permeable PKA inhibitor (KT5720)
that binds to the catalytic subunits of the cAMP depend-
ent PKA was used [17,50,60]. KT5720 (1 μM, 15 min)
decreased the amplitudes of monosynaptic EPSCs evoked
at the PB-CeLC and BLA-CeLC synapses in neurons
recorded in slices from arthritic rats (n = 7; Figure 2B,D)
but not in control neurons from normal rats (n = 7; Figure
2A,C). The inhibitory effect of KT5720 was significant
compared to predrug (ACSF) control values obtained inMolecular Pain 2008, 4:26 http://www.molecularpain.com/content/4/1/26
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the same neurons (P < 0.05, paired t-test, Figure 2D). To
confirm that the effect of KT5720 was due to a direct
action inside the CeLC neurons, KT5720 was applied into
the cell through the patch pipette filled with internal solu-
tion containing KT5720 (1 μM; Figure 2E). Monosynaptic
EPSCs evoked at the PB-CeLC synapse were measured
immediately after whole-cell patch configuration was
obtained (n = 4 neurons). EPSC amplitude decreased 9
min after the patch formation when the PKA inhibitor had
entered the cell. The inhibitory effect of intracellularly
applied KT5720 was significant compared to the control
value obtained immediately after the patch formation (P
< 0.001, repeated measures ANOVA followed by Dun-
nett's Multiple Comparison Test).
A membrane-permeable competitive cAMP antagonist
(cAMPS-Rp) that blocks PKA activation by binding to the
regulatory subunits without dissociating the kinase
holoenzyme [51] also inhibited synaptic plasticity (Figure
3B,D) but had no effect on normal synaptic transmission
(Figure 3A,C). cAMPS-Rp (10 μM, 15 min) decreased the
monosynaptic EPSCs evoked at the PB-CeLC and BLA-
CeLC synapses in slices from arthritic rats (n = 6 neurons)
but not in control neurons from normal animals (n = 4).
The inhibitory effect of cAMPS-Rp was significant com-
pared to predrug (ACSF) control values obtained in the
same neurons (P < 0.05, paired t-test, Figure 3D).
Inhibition of ERK activation decreases pain-related 
synaptic plasticity
A recent behavioral study showed antinociceptive effects
of an ERK inhibitor administered into the CeLC [2]. How-
ever, the contribution of ERK to synaptic transmission
and plasticity in the CeLC is unknown. We used a mem-
brane-permeable selective inhibitor of ERK activation
(U0126) and its inactive structural analogue (U0124, see
below) [52]. U0126 (1 μM, 15 min) inhibited synaptic
plasticity in neurons from arthritic rats (n = 6 neurons;
Figure 4B,) but had no effect on basal synaptic transmis-
sion in neurons from normal rats (n = 6; Figure 4A,C). The
inhibition of synaptic plasticity by U0126 was significant
compared to predrug (ACSF) control values obtained in
the same neurons (P < 0.05, paired t-test; Figure 4D).
PKA and ERK inhibitors have additive effects on NMDA 
receptor-mediated synaptic transmission
NMDA receptors mediate synaptic plasticity in the CeLC
in the arthritis pain model but do not contribute to basal
synaptic transmission under normal conditions [17]. PKA
and ERK inhibitors selectively affect synaptic plasticity but
not normal transmission (Figures 2, 3, 4) and can phos-
phorylate NMDA receptors [41-43]. Therefore, we
hypothesized that NMDA receptors were the target of
these protein kinases. KT5720 (1 μM, 15 min) inhibited
the pharmacologically (with NBQX, 20 μM, and bicucul-
A PKA inhibitor (KT5720) inhibits synaptic plasticity but not  normal synaptic transmission Figure 2
A PKA inhibitor (KT5720) inhibits synaptic plasticity 
but not normal synaptic transmission. Monosynaptic 
EPSCs were evoked at the PB-CeLC and BLA-CeLC syn-
apses in slices from normal (A, C) and arthritic (6 h postin-
duction; B, D, E) rats. KT5720 (1 μM, 15 min) inhibited 
synaptic transmission in neurons from arthritic rats 6 h 
postinduction (D, n = 7; P < 0.05, paired t-test) but not in 
control neurons from normal rats (C, n = 7). (A, B) Original 
recordings of EPSCs (average of 8–10 EPSCs) evoked at the 
two synapses. (C, D) Averaged EPSC amplitudes (mean ± 
SE) in the presence of KT5720 normalized to predrug 
(ACSF) control values (set to 100%). (E) Time course of the 
inhibitory effect of direct intracellular application of KT5720 
(1 μM) through the patch pipette. Each symbol shows aver-
aged EPSC amplitudes (mean ± SE; n = 4) at different times 
after whole-cell configuration was obtained (t = 0). The 
inhibitory effect was significant (P < 0.001, compared to the 
first EPSC after patch formation; Dunnett's Multiple Compar-
ison Test). Insets show EPSCs (average of 8–10 trials) evoked 
at the PB-CeLC synapse at 1 min (predrug) and at 15 min 
(KT5720) after patch formation. Whole-cell voltage-clamp 
recordings were made at -60 mV. * P < 0.05, *** P < 0.001.
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line, 30 μM) isolated NMDA receptor-mediated synaptic
component in the arthritis pain model (Figure 5A, indi-
vidual example; 5B, time course and summary, n = 3 neu-
rons). The inhibitory effect was significant (P < 0.001,
compared to predrug vehicle control, repeated-measures
ANOVA with Bonferroni post-tests). The addition of
U0126 further decreased the NMDA receptor-mediated
A cAMP antagonist (cAMPS-Rp) inhibits synaptic plasticity  but not normal synaptic transmission Figure 3
A cAMP antagonist (cAMPS-Rp) inhibits synaptic 
plasticity but not normal synaptic transmission. Mon-
osynaptic EPSCs were evoked at the PB-CeLC and BLA-
CeLC synapses in slices from normal (A, C) and arthritic (6 
h postinduction; B, D) rats. cAMPS-Rp (10 μM, 15 min) 
inhibited synaptic transmission in neurons from arthritic rats 
6 h postinduction (D, n = 6; P < 0.05, paired t-test) but not in 
control neurons from normal rats (C, n = 4). (A, B) Original 
recordings of EPSCs (average of 8–10 EPSCs) evoked at the 
two synapses. (C, D) Averaged EPSC amplitudes (mean ± 
SE) in the presence of cAMPS-Rp normalized to predrug con-
trol values (set to 100%). Whole-cell voltage-clamp record-
ings were made at -60 mV. * P < 0.05.
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An ERK inhibitor (U0126) inhibits synaptic plasticity but not  normal synaptic transmission Figure 4
An ERK inhibitor (U0126) inhibits synaptic plasticity 
but not normal synaptic transmission. Monosynaptic 
EPSCs were evoked at the PB-CeLC and BLA-CeLC syn-
apses in slices from normal (A, C) and arthritic (6 h postin-
duction; B, D) rats. U0126 (1 μM, 15 min) inhibited synaptic 
transmission in neurons from arthritic rats 6 h postinduction 
(D, n = 6; P < 0.05, paired t-test) but not in control neurons 
(C, n = 6). (A, B) Original recordings of EPSCs (average of 
8–10 trials) evoked at the two synapses. (C, D) Averaged 
EPSC amplitudes (mean ± SE) in the presence of U0126 nor-
malized to predrug control values (set to 100%). Whole-cell 
voltage-clamp recordings were made at -60 mV. * P < 0.05.
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Additive effect of PKA and ERK inhibitors on NMDA receptor-mediated synaptic plasticity Figure 5
Additive effect of PKA and ERK inhibitors on NMDA receptor-mediated synaptic plasticity. (A, B) KT5720 (KT, 
1 μM, 15 min; n = 3) inhibited the pharmacologically (with NBQX, 20 μM; bicuculline, 30 μM) isolated NMDA receptor-medi-
ated synaptic component in slices from arthritic rats (P < 0.001, repeated-measures ANOVA with Bonferroni post-tests). Co-
application of KT5720 and U0126 (1 μM, n = 3) further decreased the synaptic response (P < 0.001, Bonferroni post-tests). 
(C, D) U0126 (1 μM, 15 min) applied alone (n = 3) or together with KT5720 (n = 3) inhibited the NMDA component in the 
arthritis pain model (P < 0.05–0.001, Bonferroni post-tests). (E) Coapplication of KT5720 and U0126 (n = 6) had a significantly 
greater effect than each compound alone (P < 0.05–0.01, one-way ANOVA with Bonferroni post-tests). A negative structural 
analogue of U0126 (U0124, 1 μM, n = 3) had no effect. Bar histograms show averaged EPSC amplitudes (mean ± SE) normal-
ized to predrug control values (set to 100%). (A, C) Monosynaptic EPSCs (average of 8–10 traces) recorded at -60 mV and 
+20 mV. (B, D) Time course of drug effects at -60 mV and +20 mV. Each symbol shows averaged EPSC amplitudes (mean ± 
SE) normalized to predrug control (set to 100%). * P < 0.05, ** P < 0.01, *** P < 0.001 (compared to predrug values); + P < 
0.05, ++ P < 0.01 (compared to each drug alone).
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EPSC (P < 0.001, Bonferroni post-tests). The same result
was obtained when U0126 was applied first and KT5720
was added subsequently (Figure 5C, individual example;
Figure 5D, time course and summary, n = 3 neurons).
Inhibition by U0126 and by coapplication of KT5720 and
U0126 was significantly different from predrug vehicle
control values (P < 0.05–0.001, repeated-measures
ANOVA with Bonferroni post-tests). Figure 5E summa-
rizes the results. KT5720 and U0126 applied together (n =
6 neurons) had a significantly greater effect on NMDA
receptor-mediated EPSCs than KT5720 or U0126 alone (P
< 0.05–0.01, one-way ANOVA with Bonferroni post-
tests). The inactive structural analogue of U0126 (U0124,
1 μM, n = 3) had no significant effect. These experiments
were done only in slices from arthritic animals because
KT5720 and U0126 had no effect on basal synaptic trans-
mission in slices from normal animals (see Figures 2 and
4).
The effect of PKA activation by forskolin does not depend 
on ERK
The additive effect of PKA and ERK inhibitors suggest that
PKA and ERK do not simply act in a serial arrangement in
which one inhibitor would occlude the effect of the other.
To confirm that PKA activation modulates synaptic trans-
mission independently of ERK activation we measured
the effect of U0126 on synaptic facilitation by forskolin-
induced PKA activation. These experiments (n = 4 neu-
rons, Figure 6) were done in slices from normal animals
to determine if forskolin could mimic the changes
observed in the arthritis pain model. Forskolin (5 μM, 15
min) increased synaptic transmission and induced an
NMDA receptor-mediated component that is normally
weak or absent in control slices but can be observed in
slices from arthritic animals [17]. U0126 (1 μM, 15 min)
had no effect on the pharmacologically (with NBQX, 20
μM, and bicuculline, 30 μM) isolated NMDA component.
KT5720 (1 μM, 1 min) inhibited the synaptic facilitation
by forskolin (Figure 6A, individual traces recorded in one
CeLC neuron; Figure 6B, time course and summary).
These results may suggest that PKA and ERK modulate
synaptic transmission through independent signaling
mechanisms.
Inhibition of PKC activation has no effect on pain-related 
synaptic plasticity
A membrane-permeable selective PKC inhibitor
(GF109203X [53]) affected neither normal synaptic trans-
mission (Figure 7A,C) nor synaptic plasticity (Figure
7B,D). GF109203X (1 μM, 15 min) had no significant
effect on the monosynaptic EPSCs evoked at the PB-CeLC
and BLA-CeLC synapses in slices from normal rats (n = 5
neurons) and in slices from arthritic rats (n = 6; P > 0.05,
paired t-test).
Inhibition of PKA activation decreases pain-related 
behaviors
To validate the significance of the electrophysiological
results, we analyzed the effects of protein kinase inhibi-
tors on supraspinally (vocalizations) and spinally (hind-
limb withdrawal reflexes) organized pain behaviors in
awake animals (Figures 8, 9, 10). Audible (<16 kHz) and
ultrasonic (25 ± 4 kHz) vocalizations were evoked by brief
(15 s) noxious (2000 g/30 mm2) stimulation of the knee
with a calibrated forceps. Hindlimb withdrawal reflex
thresholds were measured by applying pressure of increas-
ing force to the knee joint with a calibrated forceps. The
inhibitors were administered into the CeLC by microdial-
ysis in 2 groups of animals: normal animals without
arthritis and arthritic animals (6 h postinduction of arthri-
tis). In the arthritis group, pain behaviors were also meas-
ured before arthritis induction to obtain baseline controls.
Drugs were administered into the right CeLC contralateral
to the arthritis because of the strong contralateral projec-
tion of the spino-parabrachio-amygdaloid pain pathway
[6] and published data showing that the right CeLC is the
site of pain-related plasticity and pain modulation [1,2,8].
All animals had guide cannulas for the microdialysis
probes implanted on the day before the behavioral tests
(see Methods).
KT5720 (100 μM, concentration in microdialysis probe,
15 min) administered into the CeLC of normal animals (n
= 5) had no significant effect on audible (Figure 8A) and
ultrasonic (Figure 8B) vocalizations and on hindlimb
withdrawal reflexes (Figure 8C). Animals in the arthritis
group (n = 6) showed significantly increased vocalizations
(P < 0.01) and decreased withdrawal thresholds (P <
0.001, repeated-measures ANOVA with Bonferroni post-
tests; Figure 8A–C). KT5720 significantly inhibited audi-
ble and ultrasonic vocalizations and significantly
increased hindlimb withdrawal thresholds (P < 0.05). The
effects were largely reversible after washout (ACSF, 30
min).
Administration of KT5720 (100 μM) into the striatum as
placement control had no effect on the significantly
increased audible and ultrasonic vocalizations (P < 0.05)
and spinal reflexes (P < 0.01, Bonferroni post-tests) of
arthritic rats (n = 4; Figure 8D–F). The striatum was cho-
sen as a control site for drug diffusion because it is adja-
cent (dorsolateral) to the CeLC but does not project to the
CeA/CeLC. The distance between the tips of the microdi-
alysis probes in the CeLC and striatum is about 2 mm. We
used this placement control successfully in our previous
studies [10,22,33]. Placement control experiments were
done only in arthritic animals because KT5720 had no
effect in the CeLC of normal animals (see Figure 8A–C).Molecular Pain 2008, 4:26 http://www.molecularpain.com/content/4/1/26
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Synaptic facilitation by forskolin is not impaired by an ERK inhibitor (U0126) Figure 6
Synaptic facilitation by forskolin is not impaired by an ERK inhibitor (U0126). PKA activation by forskolin (5 μM, 15 
min) increased transmission at the PB-CeLC synapse in slices from normal animals and induced an NMDA receptor-mediated 
component in the presence of NBQX (20 μM) and bicuculline (30 μM). U0126 (1 μM, 15 min) had no effect but KT5720 (1 
μM, 1 min) inhibited the forskolin-induced facilitation. (A) Monosynaptic EPSCs (average of 8–10 traces) recorded in an indi-
vidual CeLC neuron held at -60 mV and +20 mV. (B) Time course of drug effects at -60 mV and +20 mV (n = 4). Each symbol 
shows averaged EPSC amplitudes (mean ± SE) normalized to predrug control values (set to 100%). * P < 0.05, ** P < 0.01 
(compared to predrug values), + P < 0.05, ++ P < 0.01, +++ P < 0.001 (compared to forskolin without KT5720; repeated-
measures ANOVA with Bonferroni post-tests).
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Inhibition of ERK activation decreases pain-related 
behaviors
U0126 (100 μM, concentration in microdialysis probe)
administered into the CeLC had no significant effect on
audible (Figure 9A) and ultrasonic (Figure 9B) vocaliza-
tions and on hindlimb withdrawal reflexes (Figure 9C) in
normal animals (n = 3). Animals in the arthritis group
showed significantly increased vocalizations (n = 9, P <
0.001) and decreased withdrawal thresholds (n = 5, P <
0.001, repeated-measures ANOVA with Bonferroni post-
tests; Figure 9A–C). U0126 significantly inhibited audible
and ultrasonic vocalizations (P < 0.05) and hindlimb
withdrawal reflexes (P < 0.01).
Administration of U0126 (100 μM) into the striatum as
placement control had no effect on the significantly
increased audible (P < 0.01) and ultrasonic (P < 0.05)
vocalizations and spinal reflexes (P < 0.001, Bonferroni
post-tests) of arthritic rats (n = 4; Figure 9D–F). Placement
control experiments were done only in arthritic animals,
because U0126 had no effect in the CeLC of normal ani-
mals (Figure 9A–C).
As another control for the selectivity of U0126 the effect
of the inactive structural analogue U0124 was tested in
arthritic animals (n = 3; Figure 10A–C). Application of
U0124 (100 μM, 15 min) into the CeLC had no effect on
the significantly increased audible and ultrasonic vocali-
zations (P < 0.05) and hindlimb withdrawal reflexes (P
<0.01, Bonferroni post-tests).
Inhibition of PKC has no behavioral effect
GF109203X (100 μM, concentration in microdialysis
probe) administered into the CeLC had no significant
effect on audible (n = 9; Figure 10D) and ultrasonic (n =
9; Figure 10E) vocalizations and on hindlimb withdrawal
reflexes (n = 5; Figure 10F) in arthritic animals (6 h postin-
duction). Animals in the arthritis group showed signifi-
cantly increased vocalizations (P < 0.001) and withdrawal
reflexes (P < 0.05, repeated-measures ANOVA with Bon-
ferroni post-tests). GF109203X was tested only in arthritic
animals, because it had no effect on synaptic transmission
under normal conditions (see Figure 7A,C).
Histology
The positions of the microdialysis probes in the CeLC and
striatum (caudate-putamen) were verified histologically
(Figure 11).
Discussion
The key findings of this study are as follows. Inhibition of
PKA or ERK, but not PKC, in the CeLC decreases NMDA
receptor-mediated synaptic plasticity in the arthritis pain
model but has no effect on basal transmission under nor-
mal conditions. PKA and ERK inhibitors administered
together do not occlude each other's action but have addi-
tive effects, suggesting independent signaling pathways
for PKA and ERK. PKA activation by forskolin under nor-
mal conditions induces an NMDA receptor-mediated syn-
aptic component that mimics synaptic facilitation
A PKC inhibitor (GF109203X) has no effect on synaptic  transmission Figure 7
A PKC inhibitor (GF109203X) has no effect on synap-
tic transmission. Monosynaptic EPSCs were evoked at the 
PB-CeLC and BLA-CeLC synapses in slices from normal (A, 
C) and arthritic (6 h postinduction; B, D) rats. GF109203X 
(1 μM, 15 min) had no significant effect (P > 0.05, paired t-
test) in neurons from arthritic rats (n = 6) and in control 
neurons from normal rats (n = 5). (A, B) Original recordings 
of EPSCs evoked at the two synapses (average of 8–10 
EPSCs). (C, D) Averaged EPSC amplitudes (mean ± SE) in 
the presence of GF109203X normalized to predrug control 
values (set to 100%).
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A PKA inhibitor decreases pain-related behavior in arthritic but not in normal animals Figure 8
A PKA inhibitor decreases pain-related behavior in arthritic but not in normal animals. KT5720 (100 μM, concen-
tration in microdialysis probe, 15 min) administered into the CeLC had no significant effect on audible (A) and ultrasonic (B) 
vocalizations and on hindlimb withdrawal reflexes (C) in normal animals ("normal"; n = 5). In arthritic animals ("arthritis" in A-
C; n = 6) KT5720 significantly inhibited vocalizations and increased mechanical thresholds. In the arthritis group, behaviors 
were measured before (baseline) and 6 h after arthritis induction and during (15 min) and after (30 min washout) drug applica-
tion. (D-F) Administration of KT5720 (100 μM) into the striatum as placement control had no effect on audible and ultrasonic 
vocalizations and on spinal reflexes of arthritic rats (n = 4). Vocalizations were evoked by brief (15 s) noxious (2000 g/30 mm2) 
stimulation of the knee with a calibrated forceps. Duration of vocalizations was measured as the arithmetic sum of the duration 
of each individual vocalization event during a 1 min period beginning with the onset of the stimulus (see Methods for details). 
Bar histograms and error bars show mean ± SE. * P < 0.05, ** P < 0.01, *** P < 0.001 (repeated-measures ANOVA with Bon-
ferroni post-tests).
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An ERK inhibitor decreases pain-related behavior in arthritic but not in normal animals Figure 9
An ERK inhibitor decreases pain-related behavior in arthritic but not in normal animals. U0126 (100 μM, concen-
tration in microdialysis probe, 15 min) administered into the CeLC had no significant effect on audible (A) and ultrasonic (B) 
vocalizations and on hindlimb withdrawal reflexes (C) in normal animals ("normal"; n = 3). In arthritic animals ("arthritis" in A-
C) U0126 significantly inhibited vocalizations (n = 9) and increased mechanical thresholds (n = 5). In the arthritis group, behav-
iors were measured before (baseline) and 6 h after arthritis induction and during (15 min) and after (30 min washout) drug 
application. (D-F) Administration of U0126 (100 μM) into the striatum as placement control had no effect (n = 4). Vocaliza-
tions and withdrawal reflexes were measured as in Figure 8 (see Methods for details). Bar histograms and error bars represent 
mean ± SE. * P < 0.05, ** P < 0.01, *** P < 0.001 (repeated-measures ANOVA with Bonferroni post-tests).
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An inactive structural U0126 analogue (U0124) and a selective PKC inhibitor (GF109203X) have no effect on pain behavior Figure 10
An inactive structural U0126 analogue (U0124) and a selective PKC inhibitor (GF109203X) have no effect on 
pain behavior. (A-C) Application of U0124 (100 μM, 15 min) into the CeLC had no effect on the significantly increased audi-
ble and ultrasonic vocalizations and on the decreased hindlimb withdrawal thresholds of arthritic rats (n = 3). (D-F) 
GF109203X (100 μM, 15 min) administered into the CeLC had no effect on the significantly increased vocalizations (n = 9) and 
on decreased withdrawal reflexes (n = 5) of arthritic rats. Vocalizations and withdrawal reflexes were measured as in Figure 8 
(see Methods for details). Bar histograms and error bars represent mean ± SE. * P < 0.05, ** P < 0.01, *** P < 0.001 (repeated-
measures ANOVA with Bonferroni post-tests).
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Histologic verification of drug application sites Figure 11
Histologic verification of drug application sites. Standard diagrams [adapted from [54]] show coronal sections through 
the right brain hemisphere at different levels posterior to bregma (-1.88 mm and -2.12 mm). Symbols show the positions of the 
tips of the microdialysis probe (length of exposed membrane = 1 mm) in the CeLC (A-C) and striatum (D, placement control) 
in the behavioral experiments. (A) Application sites of KT5720, n = 11. (B) U0126, n = 12, filled circles; U0124, n = 3, open cir-
cles. (C) GF109203X, n = 9. (D) KT5720, n = 4, filled circles; U0126, n = 4, open circles. CeM, CeL, CeLC: medial, lateral and 
laterocapsular divisions of the central nucleus of the amygdala. Calibration bar (1 mm) applies to each diagram in A-D.
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observed in the arthritis model. This effect is not blocked
by the inhibition of ERK activation, arguing against a role
of ERK downstream of PKA. Consequently, inhibitors of
PKA and ERK, but not PKC, in the CeLC decrease suprasp-
inally (vocalizations) and spinally (withdrawal reflexes)
organized pain behaviors in animals with arthritis but not
in normal animals.
The significance of these results is that in the amygdala
PKA and ERK, but not PKC, modulate information
processing and behavior through separate (not serially
arranged) signaling pathways. This is different from pain-
related plasticity in the spinal cord [39,40] and from other
models of plasticity such as hippocampal long-term
potentiation (LTP) [61], where PKA and PKC act in con-
cert to activate ERK. In dorsal horn neurons activation of
PKA, PKC, or ERK increased neuronal excitability and
inhibited transient potassium (A-type) currents. The
effects of PKA and PKC activators were blocked by inhibi-
tors of ERK signaling, suggesting that PKA and PKC act as
upstream activators of ERK [39,40]. Spinal PKA and PKC
activation has also been implicated in central sensitiza-
tion [62] and behavioral hypersensitivity [63-65] in differ-
ent pain models. More recent studies showed ERK
activation and antinociceptive effects of ERK inhibition in
the spinal cord in several pain models [reviewed by [35]].
The lack of evidence for the involvement of PKC in the
present study was somewhat surprising. However it has
been pointed out before that "studies on the effects of
PKC on NMDA receptors have yielded conflicting results,
probably because PKC has multiple effects depending on
cell type, sites of action, and variable associations of
NMDA receptors with other proteins" [42].
Our data suggest that NMDA receptors are the target of
PKA and ERK. NMDA receptors have been shown to func-
tion as "upstream" activators of protein kinases. NMDA
receptors couple directly [66] or via PKA and PKC [61,67]
to ERK activation and are involved in pain-related ERK
activation in the spinal dorsal horn [see [35]]. NMDA
receptor dependent ERK activation plays an important
role in the central sensitization of dorsal horn neurons
[68]. However, NMDA receptors are also "downstream"
targets of protein kinases. PKA, PKC, and ERK can phos-
phorylate NMDA receptors to enhance current flow
through the receptor and accelerate the kinetics of the ion
channel [41-43,69-71]. PKC mediated NMDA receptor
phosphorylation removes the magnesium block [72], ren-
dering the channel functional even at normal resting
membrane potentials as observed in the present study.
Pain-related NMDA receptor phosphorylation of spinoth-
alamic tract (STT) cells in the deep dorsal horn requires
both PKC and PKA, whereas phosphorylation in superfi-
cial dorsal horn STT cells is due to the action of PKA [73].
The contribution of ERK-mediated NMDA receptor phos-
phorylation to pain-related neuronal and behavioral
changes remains to be determined, but a recent study
showed ERK-mediated NMDA receptor phosphorylation
by brain-derived neurotrophic factor (BDNF), which can
modulate nociceptive transmission in the spinal dorsal
horn [41].
The effectiveness of protein kinase inhibitors in the
present study suggests tonic NMDA receptor phosphoryla-
tion in amygdala neurons in the arthritis pain state. Kinet-
ics of phosphorylation by PKA and ERK are fast (1–5 min)
[41,41,43]. PKA can overcome constitutive protein phos-
phatase activity and rapidly enhance NMDA receptor cur-
rents [see [42]]. Blocking phosphorylation with PKA and
ERK inhibitors would shift the balance from phosphoryla-
tion toward dephosphorylation by constitutively active
phosphatases [71]. For example, type I protein phos-
phatase (PP1) binds to an NMDA receptor-associated pro-
tein and decreases current flow through the channel [70].
Striatal enriched tyrosine phosphatase (STEP) is a compo-
nent of the NMDA receptor complex and can prevent hip-
pocampal LTP without affecting normal synaptic
transmission [74]. STEP immunoreactivity is found in cell
bodies in several brain areas, including the amygdala [75].
Therefore, the negative regulation of NMDA receptor
function by protein kinase inhibitors in the present study
can be explained by the relative dominance of constitu-
tively active phosphates.
The mechanisms leading to pain-related PKA and ERK
activation in the amygdala remain to be determined. A
variety of neuromodulator/neurotransmitter receptors,
including metabotropic glutamate receptors that are
important for pain-related plasticity in the amygdala
[12,16], have been shown to couple to ERK activation via
PKA and PKC [61]. Evidence from our previous studies
suggests that neuropeptide receptors CGRP1 and CRF1
contribute to pain-related changes in the amygdala
through a mechanism that involves PKA activation
[10,33]. If PKA and ERK are indeed activated through dif-
ferent mechanisms as the present study may suggest, neu-
ropeptide receptors could activate PKA whereas
metabotropic glutamate receptors could couple to ERK
activation.
Some methodological aspects need to be considered. The
conclusions of this study rely on the selectivity of the pro-
tein kinase inhibitors. The role of PKA was determined by
using two compounds that inhibit PKA activation through
different mechanisms. KT5720 is a widely used selective
PKA inhibitor (at nanomolar to low micromolar concen-
trations) that binds to the catalytic subunits of PKA, caus-
ing the displacement of the regulatory subunit and
thereby inhibiting the phosphorylating activity of the
kinase [50,60]. cAMPS-Rp is a competitive antagonist ofMolecular Pain 2008, 4:26 http://www.molecularpain.com/content/4/1/26
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cAMP-induced activation of PKA (selective in the low to
mid micromolar range) by interacting with cAMP binding
sites on the regulatory subunits to prevent cAMP-induced
dissociation and activation of the enzyme [51]. Both
inhibitors had similar effects. Although these compounds
are membrane permeable, we showed that direct intracel-
lular injection of KT5720 had the same effect as perfusion
of the slice, confirming an intracellular site of action.
U0126 is a well established, membrane-permeable and
highly selective inhibitor of ERK activation (at nanomolar
to low micromolar concentrations) by directly inhibiting
the mitogen-activated protein kinase kinase family mem-
bers, MEK-1 and MEK-2 [52]. The MEK/ERK-selectivity of
U0126 is supported by the fact that the inactive structural
analogue U0124 had no effect. PKA and ERK inhibitors
had additive effects that were not mimicked by a selective
PKC inhibitor (GF109203x (Toullec et al., 1991), further
arguing against non-specific effects.
In this study we used protein kinase inhibitors rather than
activators, because we sought to determine the role of
endogenously activated kinases. Exogenous activation of
PKA with forskolin was used to determine the interaction
with ERK. We did not test phorbol esters, which are com-
monly used to activate ERK, because they do so through
PKC activation [2,61], which does not appear to be
involved in arthritis pain related plasticity in our studies.
Therefore, phorbol esters would not mimic the endog-
enous situation but possibly confound the analysis of ERK
function.
Another issue concerns the use of microdialysis for drug
application in the behavioral studies. Microdialysis offers
several advantages, including continued drug delivery and
steady state levels without a volume effect [76]. However,
the dose delivered by microdialysis is not known. Based
on our previous microdialysis studies of similar-sized
non-peptide compounds, we used drug concentrations in
the microdialysis fiber that were 100 times higher than the
target concentration in the tissue [50,51,53] because of
the concentration gradient across the dialysis membrane
and diffusion in the tissue[10-14,33]. A "dilution" factor
of 100 is further supported by the qualitatively and quan-
titatively similar effects of drug concentrations applied to
the brain slices in the electrophysiological studies and
those administered by microdialysis in the behavioral
studies.
Finally, it may be surprising that the kinetics of the NMDA
component and the compound EPSC were largely similar,
whereas data in the literature suggest that NMDA recep-
tors mediate slow EPSCs of relatively long duration [for
recent review see [77]]. In addition, NMDA receptor-
mediated EPSCs could be recorded at a holding potential
of -60 mV, where NMDA receptor channels are normally
blocked by magnesium. The NMDA component was iso-
lated pharmacologically with NBQX and bicuculline and
was only present in slices from arthritic animals, which is
consistent with our previous study [17] that showed sim-
ilar characteristics of NMDA receptor-mediated synaptic
transmission in the amygdala in the arthritis pain model.
The results can be explained by the effects of receptor
phosphorylation. NMDA receptor phosphorylation
relieves the magnesium block and renders the channel
functional even at -60 mV [72]. NMDA receptor phospho-
rylation by PKA or PKC also accelerates the rise and decay
times of the ion channel [69,78], which explains the
absence of apparent differences in the kinetics of NMDA
EPSC and compound EPSC in the present study. However,
our finding that an NMDA receptor-mediated component
was difficult to detect under normal conditions even at
depolarized membrane potentials (Figure 6) may suggest
that PKA modulates NMDA receptor function through
additional mechanisms such as synaptic targeting [78].
In conclusion, the present study shows that PKA and ERK,
but not PKC, are important for pain-related plasticity in
the amygdala and for the behavioral consequences of this
activity change. PKA and ERK target the NMDA receptor
possibly through independent signaling cascades. PKA
and ERK render normally "silent" NMDA receptors func-
tional in the arthritis pain model. The independence of
PKA and ERK signaling and the lack of PKC effects in this
study are different from spinal central sensitization and
hippocampal LTP and suggest that the role of protein
kinases may be more specific than previously thought.
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